The EU approved a higher Wegovy dose for obesity, boosting weight loss in clinical trials.

Halozyme Therapeutics hit $1.4B in 2025 revenue, driven by soaring royalties from key drugs, with strong growth expected in 2026.

A phase 2b trial shows duvakitug, from Sanofi and Teva, offers lasting relief for ulcerative colitis and Crohn’s disease patients.

AbbVie beat earnings expectations in Q4 2025, raised 2026 guidance, and saw increased investor interest.

FDA accepted Roche’s drug combo for ESR1-mutated advanced breast cancer, with review due by Dec. 18, 2026.

Fractal AI's Vaidya 2.0, a healthcare AI model, scored 50.1 on a key benchmark, becoming the first to exceed 50, and integrates with India’s digital health systems for real-world medical use.

Boehringer Ingelheim India and NIPER Raebareli signed an MoU on Feb. 19, 2026, to advance pharmaceutical research and education in India.

Japan's panel backs first iPS cell therapies for Parkinson’s and heart disease, pending minister approval.

Novo Nordisk stock dropped 1.6% on Feb. 19, 2026, despite strong earnings and a new oral diabetes drug, due to weak guidance and competition.

Saskatchewan adds fourth robotic surgery system, boosting access to advanced procedures across the province.